

PATIENT NAME: KAMLESH BHOR HARI (BOBS49282) REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

CODE/NAME & ADDRESS: C000138355

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO : **0290WJ005149** 

PATIENT ID : KAMLM280482290

CLIENT BATIENT ID: (BOBS49282)

AGE/SEX :41 Years

DRAWN :

RECEIVED : 28/10/2023 14:41:11 REPORTED : 28/10/2023 19:25:03

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE ASOUMARIENDING **XRAY-CHEST RESULT PENDING ECG RESULT PENDING MEDICAL HISTORY RESULT PENDING ANTHROPOMETRIC DATA & BMI RESULT PENDING GENERAL EXAMINATION RESULT PENDING** CARDIOVASCULAR SYSTEM **RESULT PENDING** RESPIRATORY SYSTEM **RESULT PENDING** PER ABDOMEN **RESULT PENDING CENTRAL NERVOUS SYSTEM RESULT PENDING MUSCULOSKELETAL SYSTEM RESULT PENDING BASIC EYE EXAMINATION RESULT PENDING BASIC ENT EXAMINATION RESULT PENDING BASIC DENTAL EXAMINATION RESULT PENDING SUMMARY RESULT PENDING FITNESS STATUS RESULT PENDING** 

Page 1 Of 12







View Repor





PATIENT NAME: KAMLESH BHOR HARI (BOBS49282)

REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

CODE/NAME & ADDRESS: C000138355

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0290WJ005149

PATIENT ID : KAMLM280482290

CHIENT PATIENT ID: (BOBS49282)

AGE/SEX :41 Years Male

DRAWN :

RECEIVED : 28/10/2023 14:41:11 REPORTED :28/10/2023 19:25:03

Test Report Status Preliminary Results Units

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVR (#SUMMAREN) DING
ULTRASOUND ABDOMEN
RESULT PENDING
TMT OR ECHO
RESULT PENDING

Page 2 Of 12





View Details

View Report





PATIENT NAME: KAMLESH BHOR HARI (BOBS49282)

REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

CODE/NAME & ADDRESS : C000138355

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156 ACCESSION NO : **0290WJ005149** 

PATIENT ID : KAMLM280482290

CLIENT PATIENT ID: (BOBS49282)

AGE/SEX :41 Years Ma

DRAWN :

RECEIVED : 28/10/2023 14:41:11 REPORTED :28/10/2023 19:25:03

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

HAEMATOLOGY - CBC					
MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE					
BLOOD COUNTS,EDTA WHOLE BLOOD					
HEMOGLOBIN (HB)	17.2 High	13.0 - 17.0	g/dL		
RED BLOOD CELL (RBC) COUNT	5.26	4.5 - 5.5	mil/μL		
WHITE BLOOD CELL (WBC) COUNT	9.88	4.0 - 10.0	thou/µL		
PLATELET COUNT	311	150 - 410	thou/µL		
RBC AND PLATELET INDICES					
HEMATOCRIT (PCV)	47.8	40 - 50	%		
MEAN CORPUSCULAR VOLUME (MCV)	90.8	83 - 101	fL		
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	32.6 High	27.0 - 32.0	pg		
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	35.9 High	31.5 - 34.5	g/dL		
RED CELL DISTRIBUTION WIDTH (RDW)	12.2	11.6 - 14.0	%		
MENTZER INDEX	17.3				
MEAN PLATELET VOLUME (MPV)	7.5	6.8 - 10.9	fL		
WBC DIFFERENTIAL COUNT					
NEUTROPHILS	67	40 - 80	%		
LYMPHOCYTES	25	20 - 40	%		
MONOCYTES	05	2 - 10	%		
EOSINOPHILS	03	1 - 6	%		
BASOPHILS	00	0 - 2	%		
ABSOLUTE NEUTROPHIL COUNT	6.62	2.0 - 7.0	thou/µL		
ABSOLUTE LYMPHOCYTE COUNT	2.47	1 - 3	thou/µL		
ABSOLUTE MONOCYTE COUNT	0.49	0.20 - 1.00	thou/µL		
ABSOLUTE EOSINOPHIL COUNT	0.30	0.02 - 0.50	thou/µL		

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

Proite

Dr.Arpita Pasari, MD Consultant Pathologist





Page 3 Of 12

liew Details







PATIENT NAME: KAMLESH BHOR HARI (BOBS49282) REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

CODE/NAME & ADDRESS: C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

**DELHI** 

**NEW DELHI 110030** 8800465156

ACCESSION NO: 0290WJ005149

PATIENT ID : KAMLM280482290 CHIENT BATTENT ID: (BOBS49282)

AGE/SEX :41 Years

DRAWN RECEIVED: 28/10/2023 14:41:11

REPORTED :28/10/2023 19:25:03

**Test Report Status** Results **Biological Reference Interval Units Preliminary** 

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.

Dr.Arpita Pasari, MD **Consultant Pathologist** 





Page 4 Of 12





REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK PATIENT NAME: KAMLESH BHOR HARI (BOBS49282) UP ABOVE 40 MALE

CODE/NAME & ADDRESS : C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

**DELHI** 

**NEW DELHI 110030** 8800465156

ACCESSION NO: 0290WJ005149

PATIENT ID : KAMLM280482290 DRAWN

CHIENT BATTENT ID: (BOBS49282)

AGE/SEX: 41 Years

Male

RECEIVED: 28/10/2023 14:41:11

REPORTED :28/10/2023 19:25:03

**Test Report Status** Results **Biological Reference Interval Preliminary** Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

**ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD** 

E.S.R 05 0 - 14

mm at 1 hr

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD** 

HBA1C

5.2

Non-diabetic: < 5.7

%

Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested : > 8.0(ADA Guideline 2021)

ESTIMATED AVERAGE GLUCOSE(EAG)

102.5

< 116.0

mg/dL

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sédimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging.
Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. **Decreased** in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

#### REFERENCE :

- 1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for The adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:
- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.



Dr. Arpita Pasari, MD **Consultant Pathologist** 





Page 5 Of 12

View Report

**PERFORMED AT:** 

Agilus Diagnostics Ltd. Gate No 2, Residency Area, Opp. St. Raphaels School, Indore, 452001 Madhya Pradesh, India





REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK PATIENT NAME: KAMLESH BHOR HARI (BOBS49282) UP ABOVE 40 MALE

CODE/NAME & ADDRESS : C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

**DELHI** 

**NEW DELHI 110030** 8800465156

ACCESSION NO: 0290WJ005149

PATIENT ID : KAMLM280482290

CHIENT BATTENT ID: (BOBS49282)

AGE/SEX :41 Years

DRAWN

RECEIVED: 28/10/2023 14:41:11 REPORTED :28/10/2023 19:25:03

**Test Report Status** Results Biological Reference Interval Units **Preliminary** 

- 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
- 2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c 46.7

- **HbA1c Estimation can get affected due to :**1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
- 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr. Arpita Pasari, MD **Consultant Pathologist** 



Page 6 Of 12





PATIENT NAME: KAMLESH BHOR HARI (BOBS49282)

REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

CODE/NAME & ADDRESS: C000138355

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO : 0290WJ005149

PAΠENT ID : KAMLM280482290

CLIENT PATIENT ID: (BOBS49282)

AGE/SEX :41 Years

DRAWN :

RECEIVED : 28/10/2023 14:41:11 REPORTED :28/10/2023 19:25:03

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

## **IMMUNOHAEMATOLOGY**

#### MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

# **ABO GROUP & RH TYPE, EDTA WHOLE BLOOD**

ABO GROUP TYPE A
RH TYPE POSITIVE

#### Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Appita

Dr.Arpita Pasari, MD Consultant Pathologist





Page 7 Of 12

View Details





REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK PATIENT NAME: KAMLESH BHOR HARI (BOBS49282)

UP ABOVE 40 MALE

CODE/NAME & ADDRESS : C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

**NEW DELHI 110030** 8800465156

ACCESSION NO: 0290WJ005149

PATIENT ID : KAMLM280482290 CLIENT PATIENT ID: (BOBS49282)

AGE/SEX :41 Years DRAWN

RECEIVED: 28/10/2023 14:41:11

REPORTED :28/10/2023 19:25:03

**Test Report Status** Results **Biological Reference Interval Units Preliminary** 

	BIOCHEMISTRY						
MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE							
GLUCOSE FASTING, FLUORIDE PLASMA							
FBS (FASTING BLOOD SUGAR)	88	74 - 99	mg/dL				
GLUCOSE, POST-PRANDIAL, PLASMA							
PPBS(POST PRANDIAL BLOOD SUGAR)	92	Normal: < 140, Impaired Glucose Tolerance:140-199 Diabetic > or = 200	mg/dL				
LIPID PROFILE WITH CALCULATED LDL							
CHOLESTEROL, TOTAL	178	Desirable: <200 BorderlineHigh: 200-239 High: > or = 240	mg/dL				
TRIGLYCERIDES	149	Desirable: < 150 Borderline High: 150 - 199 High: 200 - 499 Very High: > or = 500	mg/dL				
HDL CHOLESTEROL	40	< 40 Low > or = 60 High	mg/dL				
CHOLESTEROL LDL	108 High	Adult levels: Optimal < 100 Near optimal/above optimal 100-129 Borderline high: 130-159 High: 160-189 Very high: = 190	mg/dL :				
NON HDL CHOLESTEROL	138 High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL				
VERY LOW DENSITY LIPOPROTEIN	29.8	< or = 30	mg/dL				
CHOL/HDL RATIO	4.5 High	3.3 - 4.4					
LDL/HDL RATIO	2.7	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Modera Risk >6.0 High Risk					

Dr.Arpita Pasari, MD **Consultant Pathologist** 





Page 8 Of 12

View Report





PATIENT NAME: KAMLESH BHOR HARI (BOBS49282) REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

CODE/NAME & ADDRESS: C000138355

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO : 0290WJ005149

PATIENT ID : KAMLM280482290

CHIENT BATIENT ID: (BOBS49282)

AGE/SEX :41 Years

DRAWN :

RECEIVED : 28/10/2023 14:41:11 REPORTED :28/10/2023 19:25:03

	į	<u> </u>	
Test Report Status <u>Preliminary</u>	Results	Biological Reference I	nterval Units
LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL	0.43	0.0 - 1.2	mg/dL
BILIRUBIN, DIRECT	0.19	0.0 - 0.2	mg/dL
BILIRUBIN, INDIRECT	0.24	0.00 - 1.00	mg/dL
TOTAL PROTEIN	8.1	6.4 - 8.3	g/dL
ALBUMIN	5.3 High	3.50 - 5.20	g/dL
GLOBULIN	2.8	2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO	1.9	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	22	UPTO 40	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT)	20	UP TO 45	U/L
ALKALINE PHOSPHATASE	78	40 - 129	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT)	22	8 - 61	U/L
LACTATE DEHYDROGENASE	193	135 - 225	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	9	6 - 20	mg/dL
CREATININE, SERUM			
CREATININE	1.08	0.70 - 1.20	mg/dL
BUN/CREAT RATIO			
BUN/CREAT RATIO	8.33	5.0 - 15.0	
URIC ACID, SERUM			
URIC ACID	7.6 High	3.5 - 7.2	mg/dL
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	8.1	6.4 - 8.3	g/dL
ALBUMIN, SERUM			
ALBUMIN	5.3 High	3.5 - 5.2	g/dL
GLOBULIN			
GLOBULIN	2.8	2.0 - 4.1	g/dL
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	141.3	136.0 - 146.0	mmol/L
POTASSIUM, SERUM	5.01	3.50 - 5.10	mmol/L
CHLORIDE, SERUM	103.0	98.0 - 106.0	mmol/L

Popita

Dr.Arpita Pasari, MD Consultant Pathologist



Page 9 Of 12

View Details

View Report





REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK PATIENT NAME: KAMLESH BHOR HARI (BOBS49282) UP ABOVE 40 MALE

CODE/NAME & ADDRESS : C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

**NEW DELHI 110030** 8800465156

ACCESSION NO: 0290WJ005149

PATIENT ID : KAMLM280482290

CHIENT BATTENT ID: (BOBS49282)

DRAWN

AGE/SEX: 41 Years

Male

RECEIVED: 28/10/2023 14:41:11

REPORTED :28/10/2023 19:25:03

**Test Report Status** Results Biological Reference Interval Units **Preliminary** 

#### Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides.

Decreased in : Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

**NOTE:** While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

**ALP** is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic

syndrome, Protein-losing enteropathy etc. **Albumin** is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

permeability or decreased lymphatic clearance,malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol,

Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels: Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels: Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN SERUM is a bischoping level for massuring that the protein in action is protein in the classic and a level of a bischoping level for massuring that the protein is a price of a level of a lev

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. **Higher-than-normal levels may be due to:** Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Arpita Pasari, MD Consultant Pathologist Page 10 Of 12





View Details

View Report





PATIENT NAME: KAMLESH BHOR HARI (BOBS49282)

REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

CODE/NAME & ADDRESS : C000138355

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

**DELHI** 

NEW DELHI 110030 8800465156 ACCESSION NO: 0290WJ005149

PATIENT ID : KAMLM280482290

CHIENT PATIENT ID: (BOBS49282)

AGE/SEX :41 Years

DRAWN :

RECEIVED : 28/10/2023 14:41:11

REPORTED :28/10/2023 19:25:03

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

## **CLINICAL PATH - URINALYSIS**

#### MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

## PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

APPEARANCE CLEAR

**CHEMICAL EXAMINATION, URINE** 

5.5 4.7 - 7.5SPECIFIC GRAVITY 1.015 1.003 - 1.035 **PROTEIN** NOT DETECTED NOT DETECTED **GLUCOSE** NOT DETECTED NOT DETECTED KETONES NOT DETECTED NOT DETECTED **BLOOD** NOT DETECTED NOT DETECTED **BILIRUBIN** NOT DETECTED NOT DETECTED UROBILINOGEN **NORMAL NORMAL NITRITE NOT DETECTED** NOT DETECTED LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS

NOT DETECTED

NOT DETECTED

/HPF

PUS CELL (WBC'S)

1-2

0-5

/HPF

EPITHELIAL CELLS

2-3

0-5

/HPF

CASTS NOT DETECTED
CRYSTALS NOT DETECTED

BACTERIA NOT DETECTED NOT DETECTED
YEAST NOT DETECTED NOT DETECTED

REMARKS Please note that all the urinary findings are confirmed manually as well.

Dr.Arpita Pasari.

Dr.Arpita Pasari, MD Consultant Pathologist





Page 11 Of 12

iew Details

View Report







PATIENT NAME: KAMLESH BHOR HARI (BOBS49282)

REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

CODE/NAME & ADDRESS: C000138355

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

**DELHI** 

NEW DELHI 110030 8800465156 ACCESSION NO : **0290WJ005149** 

PATIENT ID: KAMLM280482290

on !DRAWN

DRAWN : RECEIVED : 28/10/2023 14:41:11

AGE/SEX :41 Years

REPORTED :28/10/2023 19:25:03

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

#### SPECIALISED CHEMISTRY - HORMONE

## MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

## THYROID PANEL, SERUM

Т3	81.54	80.0 - 200.0	ng/dL
T4	5.68	5.10 - 14.10	μg/dL
TSH (ULTRASENSITIVE)	3.630	0.270 - 4.200	μIU/mL

\*\*End Of Report\*\*

Please visit www.agilusdiagnostics.com for related Test Information for this accession

#### **CONDITIONS OF LABORATORY TESTING & REPORTING**

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
  - i. Specimen received is insufficient or inappropriate
  - ii. Specimen quality is unsatisfactory
  - iii. Incorrect specimen type
  - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

#### **Agilus Diagnostics Ltd**

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Proita

Dr.Arpita Pasari, MD Consultant Pathologist





Page 12 Of 12

View Details

View Report



